J. Zhang

发表

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%

S. Digumarthy, J. Roth, M. Mino‐Kenudson, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma.

W. Liang, Ying Huang, Jing Zhang, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.

H. Keizer, C. Punt, H. Lochs, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

H. Ji, F. Hirsch, P. Bunn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer

Z. Shao, Leiping Wang, Biyun Wang, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

MiR-566 protects the malignant progression of breast cancer by negatively regulating WNT6.

T. Li, B. Wang, J. Zhang, 2020, European review for medical and pharmacological sciences.

Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer.

C. Punt, C. Blanke, J. Zhang, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Objective response of first-line chemotherapy of triple-negative breast cancer translates into survival benefit: an analysis in an independent, prospective clinical trial and a real-world setting.

T. Li, Y. Zhu, J. Zhang, 2020, Neoplasma.

LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE)

J. Bergh, C. Hudis, W. Gradishar, 2014 .

Norepinephrine attenuates CXCR4 expression and the corresponding invasion of MDA-MB-231 breast cancer cells via β2-adrenergic receptors.

Z. Shao, J. Jin, F. Lv, 2015, European review for medical and pharmacological sciences.

A First-In-Human Dose-Finding Study of the Alk/Egfr Inhibitor AP26113 in Patients with Advanced Malignancies

T. Clackson, A. Shaw, S. Gettinger, 2012 .

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PF-00337210, a highly selective VEGFR inhibitor.

P. LoRusso, D. Shalinsky, A. Ricart, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.

D. Brizel, A. Monnier, F. Eschwège, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer.

D. Brizel, R. Sauer, T. Wasserman, 2000, International journal of radiation oncology, biology, physics.

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

M. Ahn, E. Felip, K. Emancipator, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Multidisciplinary analysis of evolution based Abiraterone treatment for metastatic castrate resistant prostate cancer

R. Gatenby, J. Zhang, J. Cunningham, 2021, medRxiv.

Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer.

C. Zhou, G. Schmid‐Bindert, J. Zhang, 2011, Advances in medical sciences.

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

E. Felip, M. Hellmann, M. Chatterjee, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC)

K. Blackwell, A. Forero, P. Schmid, 2016 .

Treatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective study.

B. Melosky, G. Liu, K. Osenenko, 2016, Current oncology.

Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response.

I. Pastan, E. Sharon, A. Ling, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract OT1-03-15: The METRIC trial: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC)

R. Nanda, L. Fehrenbacher, A. Forero, 2016 .